Tiziana Life Sciences Ltd has announced that members of its senior leadership team will present at the Jefferies Healthcare Conference in London from November 16-19, 2026. This presentation is significant as it comes on the heels of the company's recent positive Phase 2a INFORM-MS trial results for its lead candidate, intranasal foralumab, which targets non-active secondary progressive multiple sclerosis (na-SPMS).

The conference presentation will feature a corporate overview and a detailed discussion of the trial results, which were shared during a Key Opinion Leader (KOL) call on November 9, 2026. The positive outcomes from the INFORM-MS trial are expected to attract attention from investors and industry experts alike.

Background

Tiziana Life Sciences is a clinical-stage biopharmaceutical company specializing in innovative therapies for immunomodulation. The company operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. Tiziana is publicly traded on the Nasdaq under the ticker TLSA.

What the Filing Says

According to the filing dated November 12, 2026, Tiziana will present at the Jefferies Healthcare Conference, stating, "The presentation will feature a corporate overview and discussion of the Company’s recent positive Phase 2a INFORM-MS topline results for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS)." This follows the KOL call held on November 9, 2026.

Impact

This announcement may significantly impact stakeholders, including investors, healthcare professionals, and competitors in the pharmaceutical industry. The positive trial results position Tiziana favorably in the competitive landscape of treatments for multiple sclerosis, potentially influencing market dynamics.

What's Next

Following the conference, Tiziana may provide further updates based on the feedback received and any additional developments regarding their clinical trials. The filing does not specify what happens next.